摘要
目的:评价脑梗死急性期帕罗西汀、多奈哌齐联合治疗对卒中后抑郁的有效性。方法:收集2012年10月-2014年7月在本院住院治疗的急性脑梗死患者79例,随机数字表法分成两组。试验组帕罗西汀20 mg,每日1次晨服,连续3个月;多奈哌齐5 mg,每日1次晨服,自入院24 h开始连续服用2周后停药。对照组仅给予帕罗西汀20 mg口服,1次/d,共3个月。治疗后3个月后两组患者分别进行汉密尔顿抑郁量表(HAMD)评分、改良的Rankin量表(3个月m RS)评分,比较两组的临床疗效。结果:试验组3个月的HAMD评分、3个月m RS量表与对照组比较均改善明显(P<0.05)。治疗过程中均未发生严重不良反应。结论:脑梗死急性期帕罗西汀、多奈哌齐联合治疗可以改善急性脑梗死患者预后、减轻致残,具有较高的安全性.
Objective：To evaluate the efficacy and safety of Donepezil combined with Paroxetine at acute cerebral infarction in the treatment of post-stroke depression.Method：79 patients with post-stroke depression were randomly divided into two groups from October 2012 to July 2014, among which 41 cases as experimental group, and 38 cases as control group.Experimental group was treated with Donepezil.It was 5 mg/d within the first 14 days.Additionally,20 mg Paroxetine was given once a day for 90 days.Control group was only treated with 20 mg Paroxetine was given once a day for 90 days.The degree of neurological deficit was compared using the Hamilton Depression Scale（HAMD）and modifies Rankin Scale（mRS）scoring between the two groups after treatment respectively.Result：Hamilton Depression Scale was significantly improved,and the modifies Rankin Scale were significant enhanced in the experimental group when compared with the control（P〈0.05）.No serious adverse reaction occurred during treatment.Conclusion：Donepezil combined with Paroxetine at acute cerebral infarction which has a higher security probably improves the prognosis and reduces the disability of patients with post-stroke depression.
出处
《中国医学创新》
CAS
2015年第12期53-55,共3页
Medical Innovation of China
基金
广东省医学科研基金青年项目(B2013410)
关键词
脑梗死
帕罗西汀
多奈哌齐
卒中后抑郁
Brain infarction
Paroxetine
Donepezil
Post-stroke depression
